EBGLYSS
lebrikizumab-lbkz
- Strength
- 250 mg/2mL
- Form
- Injection, Solution
- Class
- Interleukin-13 Antagonist
Eli Lilly and Company
Not stocked by us — reference only
lebrikizumab-lbkz
Listed by Eli Lilly and Company
| Dosage form | Injection, Solution |
|---|---|
| Route | Subcutaneous |
| Drug class | Interleukin-13 Antagonist |
| Approval route | BLA — biologic licence |
| NDC code | 0002-7772 |
| FDA application | BLA761306 |
| RxNorm concept | 2693784 |
| Package sizes listed | 2 |
| Marketed since | September 2024 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
lebrikizumab-lbkz
Eli Lilly and Company
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.